Company news
Plus Therapeutics, Inc. news in 2022
Plus Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Plus Therapeutics Provides Updates on ReSPECT™ Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
November 18, 2022
Plus Therapeutics Announces Selection of “Rhenium (186Re) Obisbemeda” as International Non-Proprietary Name for 186RNL
October 25, 2022
Plus Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on October 20, 2022
October 5, 2022
Plus Therapeutics Executes $17.6 Million Award Contract with Cancer Prevention & Research Institute of Texas
September 21, 2022
Plus Therapeutics Presents Positive Phase 1 Data from ReSPECT-GBM Clinical Trial at the European Society for Medical Oncology Congress 2022
September 11, 2022
Plus Therapeutics Announces FDA Meeting Summary for Lead Drug Candidate
September 5, 2022
Plus Therapeutics Announces Summary of FDA Meeting on Company’s cGMP Manufacturing Process for Lead Drug Candidate
August 28, 2022
Plus Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
July 20, 2022
Plus Therapeutics Successfully Completes Key Milestone for cGMP Manufacture of Lead Investigational Radiotherapeutic
July 11, 2022
Plus Therapeutics and Biocept Announce Comprehensive Laboratory Services Agreement for the ReSPECT-LM Trial
June 21, 2022
Plus Therapeutics Completes Enrollment of Cohort 1 ReSPECT-LM Phase 1/2a Trial
June 15, 2022
Plus Therapeutics Reports Positive Clinical Outcomes from ReSPECT-GBM Trial at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting
June 12, 2022
Plus Therapeutics Announces Oral Presentation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting
April 18, 2022
Plus Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting
April 7, 2022
Plus Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of 186RNL Radiotherapeutic for Leptomeningeal Metastases
March 21, 2022
Plus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
February 23, 2022
Plus Therapeutics Partners with Medidata to Apply Innovative Synthetic Control ArmⓇ Solution to Accelerate Brain Cancer Clinical Trial
February 21, 2022
Plus Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 24, 2022
February 17, 2022
Plus Therapeutics Significantly Expands Investigational Oncology Drug Pipeline
January 5, 2022
Plus Therapeutics Announces Two Significant Milestones Toward cGMP Manufacture of its Lead Investigational Radiotherapeutic
January 3, 2022
Calls in 2022
- PLUS THERAPEUTICS (NASDAQ:PSTV) Q3 2022 Earnings Call
Oct 20, 2022
Transcript - PLUS THERAPEUTICS (NASDAQ:PSTV) Q2 2022 Earnings Call
Jul 21, 2022
Transcript - PLUS THERAPEUTICS (NASDAQ:PSTV) Q1 2022 Earnings Call
Apr 21, 2022
Transcript - PLUS THERAPEUTICS (NASDAQ:PSTV) Q4 2021 Earnings Call
Feb 24, 2022
Transcript